FST (036810) Stock Outlook 2026: Pellicle Franchise and the EUV Localization Call Option

Is FST a materials name or an EUV story?

The confusion around FST comes from having two different businesses under one ticker. One makes money today: photomask pellicles, temperature-control chillers, and process parts sold into Korea’s fabs. The other is a bet on tomorrow: localizing the EUV pellicle, one of the hardest consumables in advanced lithography. Value the stock without separating those two, and you cannot tell whether it is cheap or expensive.

My read is straightforward. FST is a solid, cash-generating supplier of semiconductor consumables and parts, with a call option bolted on top in the form of EUV localization. The base business grinds through the cycle on its own. If the EUV pellicle turns into real customer orders, the market re-rates the whole thing as a growth story. The catch is that the market tends to price a chunk of that option in advance, so the shares swing on two axes at once: the memory capex cycle and EUV localization headlines.

Buy it purely as an “EUV theme stock” and you get frustrated in the quiet stretches between news. Treat it as “just another materials name” and you miss the upside if localization actually lands. You have to hold both faces of the company in your head.

Set it beside a Korean etchant-and-precursor supplier like Soulbrain in this outlook and the texture of the materials cycle gets a lot clearer.

The pellicle base business: a consumable moat

A pellicle is, in one line, a dust cover for a photomask. In lithography the mask is the master carrying the circuit pattern, and a single particle landing on it repeats as a defect on every wafer printed. The pellicle is a thin film suspended a fixed distance above the mask. Any contaminant that lands on the film sits outside the focal plane, so it never images onto the wafer.

The business consequence matters: a pellicle is a consumable. As long as the mask is in use, pellicles get replaced, and demand recurs for as long as the customer’s line runs. This is not a sell-it-once equipment sale; revenue flows the entire time a fab is producing. In razor-and-blade terms, the pellicle is the blade.

FST’s moat in the base business rests on a few layers:

• Qualification barriers. Pellicles must pass a customer’s quality qualification for a specific mask and process before they ship. Once approved, a supplier is not swapped casually, because any micro-defect means yield loss and customers hate disturbing a validated supply chain.
• Domestic supply-chain position. A long track record supplying Korea’s big fabs is the foundation of trust, and the value of that position grows as material localization becomes a national priority.
• A wavelength ladder. The DUV (ArF/KrF) pellicle market is mature but a dependable cash cow, and that cash funds the leap to the next generation.

None of that makes the base business a fortress. DUV pellicles are a slow-growth mature market, and S&S Tech competes at home. On its own, the base business is best described as steady but capped. The explosive upside lives in the next section.

EUV pellicle localization: where the option value comes from

The story that puts a premium on FST is the EUV pellicle. It helps to understand why the problem is so hard, and why doing it domestically is worth money.

EUV lithography uses 13.5nm extreme-ultraviolet light, and that light is absorbed by nearly everything. Yet the pellicle sits squarely in the beam path. Light travels to the mask, reflects, and passes through the pellicle twice, so even a small drop in transmittance costs a lot of exposure dose and wrecks tool throughput. That forces an extremely high transmittance target. On top of that, as scanner source power climbs into the hundreds of watts, the thin membrane takes savage thermal stress and must hold its shape without sagging or deforming, exposure after exposure. Transmittance, heat tolerance, and mechanical strength all at once, in a film thin enough to let EUV through. That trifecta is why only Mitsui Chemicals and ASML’s internal program have meaningfully served this space.

So why is localizing it a business opportunity?

Attribute	DUV pellicle	EUV pellicle
Engineering difficulty	Mature	Very high
Number of suppliers	Many	Very few
Localization status	Achieved	Entry attempts
Price / margin	Ordinary	High premium expected
Demand driver	Legacy fabs	Samsung / SK hynix EUV lines

Samsung already runs EUV in leading-edge DRAM and foundry, and SK hynix is widening EUV adoption as it shrinks DRAM. For both, depending entirely on a couple of foreign pellicle suppliers is a supply-chain exposure. Between pricing leverage, volume security, and geopolitics, there is a clear incentive to cultivate a domestic option, and FST sits among the candidates. That is the source of the option value.

But an option is an option. How broadly EUV pellicles get adopted in high-volume manufacturing, and when a domestic product clears qualification, are both still open. Logic makers have at times run EUV layers without a pellicle at all, so the addressable scope itself is a variable. This is a textbook call-option payoff: large if it converts, disappointing if it slips. A name whose earnings hinge on one growth theme, like HBM tooling supplier Hanmi Semiconductor, carries a similar profile.

Chillers and process parts: a second leg that spreads the cycle

Seeing FST only as a pellicle company is half the picture. The temperature-control unit, or chiller, business is the other axis.

Etch and deposition steps demand very tight control of chamber and wafer-chuck temperature. When temperature drifts, process uniformity breaks down and yield suffers. Chillers hold that temperature steady, and within Korea’s drive to localize fab equipment FST has built a position here.

The point is that this business behaves differently from pellicles. Pellicles are a consumable tied to line utilization; chillers are closer to equipment tied to capex. When a fab builds a new line and brings in tools, chiller demand follows.

Business	Demand driver	Cycle character	Margin profile
Pellicle (DUV)	Line utilization / consumption	Relatively steady	Stable cash cow
Pellicle (EUV)	Leading-edge adoption	New growth	Premium expected
Chiller / parts	Equipment capex	Investment-cycle sensitive	Order-book driven

This is not a perfect hedge. All three businesses sit under the single umbrella of the chip cycle, so a deep downturn drags them together. Still, the timing gap between a consumable and an investment good cushions the earnings swing, and that is a genuine strength.

The chip cycle and customer concentration: the most honest risk

To forecast FST’s earnings you ultimately watch two customers: Samsung Electronics and SK hynix. That concentration is both its strength and its greatest weakness.

The strength is obvious: holding the world’s premier memory and foundry customers is itself a badge of trust. The weakness is the flip side. When revenue clusters on a few buyers, bargaining power tilts toward them. If a customer defers investment, results slip; if it demands a price-down, margins compress. A change in one customer’s process roadmap becomes an earnings variable overnight.

Layer on the chip cycle. When memory prices rise and supply discipline eases into full-tilt fab utilization, consumable and parts demand revives; in oversupply and inventory correction, capex gets pushed out and back-end materials names get hit first. A small-cap materials supplier like FST tends to feel the amplitude of that cycle more than the large caps.

Phase	Customer capex / utilization	Effect on FST
Memory upturn, full utilization	Capex up, lines full	Pellicle use up, chiller orders up
Peak, inventory correction	Investment on hold, softer utilization	Deferred parts demand, price pressure
Downcycle	Capex cut, output curbs	All segments contract, earnings fall sharply
EUV transition accelerates	Leading-edge investment concentrates	EUV pellicle opportunity in focus

Cross-check the DRAM and HBM backdrop through SK hynix and the HBM cycle, and gauge a set maker’s spending headroom via Samsung Electronics’ outlook; together they help you read FST’s downstream demand.

For a foreign investor: access, currency, and tax

Owning FST is not like owning a US chip stock. There is no ADR. The shares trade only on KOSDAQ in Korean won, so you buy directly on the Korea Exchange through a broker with Korean-market access. Korea has streamlined foreign portfolio-investor access in recent years, but you still take on won exposure and local settlement.

Three practical implications:

• Currency is a second position. Your return is the stock return times the KRW move. A weakening won can erase a decent local gain when translated back to dollars, and vice versa. FST’s own margins also flex with USD/KRW because materials inputs and export competitiveness both run through the exchange rate.
• No US-listed proxy. You cannot express this thesis through a dollar-denominated ADR, and there is no clean listed substitute. It is the KOSDAQ line or nothing.
• Tax is residence-specific. Foreign portfolio investors below the relevant ownership thresholds are generally exempt from Korean capital gains tax on listed shares, while dividends face Korean withholding reduced by an applicable treaty. Confirm the treaty rate for your country with an adviser rather than assuming.

If you want the broader frame for sizing a thematic growth name inside a portfolio, the AI stocks investment guide lays out the position-sizing logic.

Competitive landscape: S&S Tech, Mitsui, and ASML

Competitive axis	Representative	Nature of the threat
Domestic direct rival	S&S Tech	Blankmask + pellicle, chasing EUV in parallel
Global pellicle leader	Mitsui Chemicals	Long-held DUV/EUV supply position
EUV in-house solution	ASML	Tool-vendor internalization of EUV pellicles
Parts / chiller substitution	Various suppliers	Nibbling at specific segments

The pivotal question is who wins the domestic EUV pellicle race: whether FST or S&S Tech gets qualified first, at which customer, and in what form. Both share the same localization narrative, so a single customer’s choice can split their relative valuations sharply. Globally, the EUV roadmap of the sole scanner supplier, ASML, sets the ceiling on EUV pellicle demand.

A growing market is the cushion. As EUV adoption spreads across memory and logic, the pellicle pie itself expands, and the localization direction is underwritten by supply-security and policy logic even when competition is fierce.

Risk check and what to watch each quarter

Before getting drunk on the growth story, weigh these honestly: the EUV option may not convert if qualification slips; customer concentration means one buyer’s decision is an earnings shock; small-cap amplitude means deeper drawdowns in a downcycle; competition from S&S Tech and Mitsui pressures price and share; USD/KRW drives both input costs and foreign flows; and the valuation carries two-way leverage, expanding fast when the theme is hot and compressing hard when enthusiasm cools.

Track it in this order each quarter:

1. EUV pellicle progress and orders — development stage, customer qualification, first commercial order. This is the re-rating trigger.
2. Memory and foundry capex direction — Samsung and SK hynix investment signals, the compass for downstream demand.
3. Customer fab utilization — full-tilt versus curtailment sets pellicle consumption.
4. Chiller and parts order flow — tied to the equipment investment cycle.
5. USD/KRW — hits costs, margins, and foreign flows at once.

Read those five together and you can separate the base-business cycle from real EUV progress, instead of reacting to a single headline revenue number.

---

This article is for informational purposes only and is not a recommendation to buy or sell any security. Investing carries the risk of loss of principal, and every decision should reflect your own financial situation and risk tolerance. Tax treatment depends on your country of residence and applicable treaties, and the company details described here reflect the time of writing; verify the latest disclosures and consult a qualified adviser before investing.